[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"guillain-barr-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:guillain-barr-syndrome":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,46,78,111,136],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100588400","living-with-guillain-barr-syndrome-as-children-100588400",false,"NCT06940908","Living With Guillain-Barré Syndrome as Children.","Experience of Guillain Barré Syndrome in Childhood: A French Multicentric Qualitative Study","GUIREQUAL","Inclusion Criteria:\n\n* Children or adolescents aged 10 years or older at the time of the interview\n* History of Guillain-Barré syndrome (GBS) diagnosed in childhood\n* Time since acute episode: between 2 and 5 years\n* Sufficient mastery of the French language to participate in a semi-structured interview\n* Consent of the participant and, for minors, parental consent\n\nExclusion Criteria:\n\n* Presence of a neurological disease other than GBS that may interfere with participation or interpretation of data\n* Severe cognitive impairment preventing the child or adolescent from engaging in the interview","ALL","10 Years","18 Years",{"count":21,"type":22},25,"ESTIMATED","OBSERVATIONAL","The goal of this qualitative observational study is to explore the lived experience and psychological aftermath of children who were affected by Guillain-Barré Syndrome (GBS) two to five years earlier. GBS is a rare and acute neurological condition, and while motor recovery is generally good in children, residual symptoms such as fatigue, pain, anxiety, or depression may persist and impact quality of life.\n\nThe main questions it aims to answer are:\n\nHow do children experience and recall their illness and recovery after GBS? What psychological or contextual factors might contribute to emotional distress or depressive symptoms in the years following the disease?\n\nParticipants will:\n\nBe children aged 10 or older who had GBS two to five years prior. Participate in a 45-60-minute semi-structured individual interview during a routine follow-up visit.\n\nRespond to a screening questionnaire for depressive symptoms (Children's Depression Inventory or Beck Depression Inventory Fast Screen).\n\nUndergo a brief clinical examination to assess any remaining physical sequelae. Interviews will be audio recorded, transcribed verbatim, and pseudonymized. Thematic reflexive analysis will be performed following Braun and Clarke's methodology. Recruitment will continue until theoretical saturation is reached (approximately 25 participants expected) across two centers (Toulouse and Montpellier).\n\nThis study aims to generate new insights into pediatric psychological outcomes after GBS, in order to improve acute care and follow-up, and potentially guide future mental health support for affected children.",[26,27],"Guillain Barré Syndrome","Guillain-Barré Syndrome (GBS)",[29,30,31,32],"children","experience","qualitative study","quality of life","RECRUITING","2026-05-07",{"date":36,"type":37},"2026-05-08","ACTUAL",{"date":39,"type":37},"2025-05-05",{"date":41,"type":22},"2027-06-01",{"name":43,"class":44},"University Hospital, Toulouse","OTHER",2,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":19,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":64,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":77},"100579279","high-tech-rehabilitation-pathway-for-acute-adult-neuromuscular-diseases---fit4medrob-acute-mnd-project-100579279","NCT06822231","High-Tech Rehabilitation Pathway for Acute Adult Neuromuscular Diseases - Fit4MedRob-Acute MND Project","Clinical Protocol for a Pragmatic Trial on a High-Tech Rehabilitation Pathway for Acute Adult Neuromuscular Diseases (Fit4MedRob-Acute MND Project)","Fit4MR-AcMND","Inclusion Criteria:\n\n* Adults with ages ranging from 18 to 80 years.\n* Patients with a confirmed diagnosis of acute\u002Fsubacute neuromuscular diseases (e.g. GBS, CIM, CIP)\n* Time of onset ranging from 15 to 30 days\n* Patients with lower limb strength (Medical Research Council or MRC) \\>=2 in at least two of the flexor and extensor muscles of the following joints: hip, knee and ankle\n* Possibility of obtaining informed consent\n\nExclusion Criteria:\n\n* Patients with unstable medical conditions (e.g. severe cardiovascular diseases, such as \"New York Heart Association\" - NYHA=4, respiratory distress not compensated by ventilation) that could interfere, in the clinician's judgment, with their ability to safely participate in the study or to perform the assessments related to the protocol.\n* Patients currently participating in other clinical trials that could interfere with this study.\n* Pregnant or breastfeeding women.","80 Years",{"count":56,"type":22},124,"INTERVENTIONAL",[59],"NA","The goal of this study is determine if a high-tech rehabilitation circuit is more effective than usual rehabilitation methods in improving functional outcome, particularly balance control, for patients with acute neuromuscolar diseases. The main question it aims to answer is:\n\nAre high-tech rehabilitation interventions, including robotic systems, virtual reality, and stabilometric platforms, more effective than traditional rehabilitation methods in improving balance, motor function, fatigue levels, sarcopenia, cognitive engagement, and overall quality of life in patients with acute neuromuscular diseases (NMDs)? Researchers will compare a robotic treatment group, that consists in an high-tech rehabilitation, with a control group, that will receive the traditional rehabilitative treatment.",[62,26,63],"Critical Illness Myopathy","Critical Illness Polyneuromyopathy (CIPNM)",[65,66,67],"high-tech rehabilitation","acute neuromuscular diseases","robotic platform","2026-03-02",{"date":70,"type":37},"2026-03-03",{"date":72,"type":37},"2025-05-28",{"date":74,"type":22},"2026-11",{"name":76,"class":44},"Istituti Clinici Scientifici Maugeri SpA",8,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":85,"sex":17,"minAge":19,"maxAge":86,"enrollmentInfo":87,"targetDuration":89,"studyType":23,"phases":4,"briefSummary":90,"conditions":91,"keywords":96,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":110},"100563396","our-study-aims-to-determine-if-nerve-alterations-in-acute-gbs-and-cidp-detectable-by-ultrasound-match-electrodiagnostic-findings-and-if-this-method-aids-early-diagnosis-predict-their-outcomes-and-differentiate-between-axonal-and-demyelinating-subtypes-100563396","NCT06615622","Our Study Aims to Determine if Nerve Alterations in Acute GBS and CIDP Detectable by Ultrasound Match Electrodiagnostic Findings and if This Method Aids Early Diagnosis, Predict Their Outcomes and Differentiate Between Axonal and Demyelinating Subtypes.","A Comparative Study of Peripheral Nerve Ultrasound Findings in Immune Mediated Peripheral Nerve Disorders; a Hospital-based Study","Inclusion Criteria:\n\n1. Diagnosis of patient group:\n\n   * GBS Patients: Diagnosed according to the criteria of the National Institute of Neurological Disorders and Stroke (NINDS) and the Brighton Collaboration (2011).\n   * CIDP Patients: Diagnosed according to the criteria of the European Federation of Neurological Societies\u002FPeripheral Nerve Society (EFNS\u002FPNS).\n2. Age: Participants aged 18 to 75 years.\n3. Onset:\n\n   * GBS Patients: Recent onset of GBS within the first 2 weeks of symptom onset.\n   * CIDP Patients: Either relapsing or progressive course consistent with CIDP diagnosis.\n4. Gender: Both male and female participants are eligible.\n5. Participation: Willingness to participate in the study, including undergoing disease-related examinations and assessments.\n6. Consent: Ability and willingness to provide informed consent\n\nExclusion Criteria:\n\n1. Patients unable or unwilling to provide informed consent.\n2. Patients with metabolic disorders or malignancies.\n3. Patients with other causes of peripheral neuropathy.\n4. Patients with other causes of acute flaccid paralysis.",true,"75 Years",{"count":88,"type":22},90,"6 Months","Neuromuscular ultrasound (NMUS) is emerging as a valuable non-invasive diagnostic tool. In GBS, NMUS can detect proximal nerve enlargement early, before neurophysiological changes. Persistent nerve enlargement can be observed up to 15 years, though its correlation with disability varies. Research is needed to clarify NMUS findings in GBS and CIDP over time. Early detection of nerve root enlargement via NMUS could facilitate earlier diagnosis and intervention, improving patient outcomes and understanding of these conditions\\' pathophysiology.\n\nThis study aims to determine if nerve alterations in acute GBS and CIDP detectable by ultrasound match electrodiagnostic findings and if this method aids early diagnosis. The investigators will perform serial nerve ultrasounds and NCS to investigate nerve morphology, predict outcomes, and differentiate between axonal and demyelinating subtypes.",[26,92,93,94,95],"Chronic Inflammatory Demyelinating Polyradiculoneuropathy","Peripheral Nerve Disorder","Peripheral Nerves US","Peripheral Neuropathy",[97,98,99,100],"Peripheral nerve ultrasound","immune mediated nerve disorders","Guillain-Barré syndrome","Chronic inflammatory demyelinating polyradiculoneuropathy","2025-10-01",{"date":103,"type":37},"2025-10-03",{"date":105,"type":37},"2024-09-01",{"date":107,"type":22},"2028-03-30",{"name":109,"class":44},"Assiut University",1,{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":115,"acronym":116,"eligibilityCriteria":117,"healthyVolunteers":11,"sex":17,"minAge":19,"maxAge":4,"enrollmentInfo":118,"targetDuration":4,"studyType":57,"phases":120,"briefSummary":121,"conditions":122,"keywords":124,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":110},"100474745","rehabgbs-rehabilitation-in-people-with-guillain-barr-syndrome-100474745","NCT05461898","RehabGBs: Rehabilitation in People With Guillain-Barré Syndrome","RehabGBs","Inclusion Criteria:\n\n* ≥18 years\n* diagnosed with Guillain Barré Syndrome\n* willing to participate in an inpatient rehabilitation program\n* able to provide informed consent\n\nExclusion Criteria:\n\n* presence of significant cardiac and musculoskeletal diseases\n* tracheostomized patients\n* signs of cognitive impairment or current neoplastic or immunological disease which may preclude their participation in the rehabilitation program and participation in any other therapeutic intervention in addition to standard of care.",{"count":119,"type":22},74,[59],"Guillain-Barré syndrome (GBS) is a neurological disease characterized by an inflammation of peripheral nerves, which might be responsible for long-term disability.\n\nRespiratory muscle weakness is a complication of GBS and might be responsible for respiratory symptoms, inadequate secretion clearance or hypoventilation, with negative impact on daily life.\n\nInspiratory muscle training has been applied in respiratory and neurological diseases and benefits have been observed in symptoms (e.g., dyspnoea), pulmonary function, exercise capacity and quality of life. Nevertheless, results of this intervention in people with GBS are yet unknown. Moreover, rehabilitation is a key player in the recovery of these highly complex patients, however, the interpretation of the magnitude of its effects has been limited by the absence of minimal clinically important differences for most outcome measures. To overcome these drawbacks, methodologically robust trials are needed to build evidence-based rehabilitation to improve clinical care on GBS.\n\nThe primary aim of this project (RehabGBs) is to develop an inspiratory muscle training protocol - InspireGBs and assess its effects on respiratory muscle strength, peak cough flow, pulmonary function, dyspnoea, fatigue, functional status and quality of life in people with GBS, through a randomised controlled trial. Secondary aims are to: i) establish minimal clinically important differences of Functional Assessment of Chronic Illness Therapy-Fatigue Subscale, Medical Research Council - Manual Muscle Testing, Vital capacity, Maximal Inspiratory Pressure, Peak Cough Flow, Functional Independence Measure and Quality of Life for inpatient rehabilitation programmes of people with GBS ii) Evaluate the prevalence of nocturnal hypoventilation in GBS.",[123],"Guillain-Barré Syndrome",[125,126],"Rehabilitation","Inspiratory Muscle Training","2025-04-01",{"date":129,"type":37},"2025-04-04",{"date":131,"type":37},"2023-01-01",{"date":133,"type":22},"2026-12-31",{"name":135,"class":44},"Centro de Reabilitacao do Norte",{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":140,"acronym":4,"eligibilityCriteria":141,"healthyVolunteers":11,"sex":17,"minAge":19,"maxAge":4,"enrollmentInfo":142,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":143,"conditions":144,"keywords":4,"overallStatus":149,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":110},"100573006","neuromuscular-complications-of-mek-inhibitors-a-french-case-series-and-a-systematic-review-of-the-literature-100573006","NCT06740656","Neuromuscular Complications of MEK Inhibitors: a French Case Series and a Systematic Review of the Literature","Inclusion Criteria:\n\n* Patients with neuromuscular complications of MEK inhibitors used alone or in combination\n* Age \\> 18 years\n\nExclusion Criteria:\n\n* Refusal of data collection",{"count":5,"type":22},"MEK inhibitors (trametinib, cobimetinib, selumetinib or binimetinib) have been used since 2016 to treat metastatic melanoma, by targeting the MAPK pathway Neuromuscular complications (neuropathy, myasthenia or myositis) have been reported in patients treated with MEK inhibitors.\n\nWith the growing use of these new oncology therapies, neurologists, oncologists and other clinicians are likely to be increasingly confronted with MEK inhibitor-induced neuropathy, myasthenia or myositis.\n\nYet, so far, these complications have only been documented in a few single case reports.\n\nOur aim was to characterize the neuromuscular complications associated with MEK inhibitors used either alone or in combination.",[145,146,147,26,148],"Myositis","Myasthaenia Gravis","Neuropathy","Parsonage Turner Syndrome","NOT_YET_RECRUITING","2025-02-16",{"date":152,"type":37},"2025-02-18",{"date":154,"type":22},"2025-03-01",{"date":156,"type":22},"2026-01-01",{"name":158,"class":44},"Central Hospital, Nancy, France"]